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Background: Mitochondrial outer membrane permeabilization (MOMP) is a crucial step leading to apoptotic
destruction of cancer cells. Bcl-2 family proteins delicately regulate mitochondrial outer membrane integrity
through protein-protein interactions, which makes the mitochondrion an ideal cell-free system for screening
molecules targeting the Bcl-2 anti-apoptotic proteins. But assay conditions need to be optimized for more reliable
results. In this study, we aimed at establishing a reliable functional assay using mitochondria isolated from breast
cancer cells to decipher the mode of action of BH3 peptides derived from BH3-only proteins. In this study, high
ionic strength buffer was adopted during the initiation of MOMP. Mitochondria isolated from human breast cancer
cell lines with distinct expression patterns of Bcl-2 anti-apoptotic proteins were permeabilized by different BH3
peptides alone or in combination, with or without the presence of recombinant anti-apoptotic Bcl-2 family proteins.
Cytochrome C and Smac/Diablo were tested in both supernatants and mitochondrial pellets by Western blotting.
Results: Sufficient ionic strength was required for optimal release of Cytochrome C. Bad and Noxa BH3 peptides
exhibited their bona fide antagonistic effects against Bcl-2/Bcl-xL and Mcl-1 proteins, respectively, whereas Bim BH3
peptide antagonized all three anti-apoptotic Bcl-2 members. Bad and Noxa peptides synergized with each other in
the induction of MOMP when mitochondria were dually protected by both Bcl-2/Bcl-xL and Mcl-1.
Conclusions: This method based on MOMP is a useful screening tool for identifying BH3 mimetics with selective
toxicity against breast cancer cell mitochondria protected by the three major Bcl-2 anti-apoptotic proteins.
Keywords: Mitochondrion, B cell lymphoma 2 (Bcl-2), Bcl-2 homolog domain 3 (BH3), Mitochondrial outer
membrane permeabilization (MOMP)Background
The mitochondrial outer membrane permeabilization
(MOMP) is a crucial step of the apoptotic process trig-
gering the release of soluble apoptogenic factors from
the intermembrane space such as Cytochrome C and
Smac/Diablo followed by subsequent activation of
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reproduction in any medium, provided the or[1]. The MOMP process is often altered in cancer cells,
resulting largely from the deregulated expression of
Bcl-2 family proteins [2]. The Bcl-2 family includes anti-
apoptotic proteins like Bcl-2, Bcl-xL, Bcl-w, and Mcl-1
containing all four Bcl-2 homology domains (BH1-4),
pro-apoptotic proteins like Bax, Bak and Bok lacking the
BH4 domain, and the pro-apoptotic BH3-only proteins
like Bim, Bid, Puma, Bad and Noxa [3]. Among all of
these proteins, Bax and Bak are believed to be the “exec-
utors” which will exhibit conformational change and
oligomerization upon activation and subsequently in-
duce MOMP and cell death.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Long et al. BMC Biotechnology 2013, 13:45 Page 2 of 10
http://www.biomedcentral.com/1472-6750/13/45There are two widely embraced models for the initi-
ation of MOMP: the direct activation model and the
indirect activation model. The direct model proposes
that a subset of BH3-only proteins termed “activators”,
namely Bim, Bid and Puma, directly engage Bax or Bak,
resulting in the activation and oligomerization of these
two proteins. Some other BH3-only proteins, termed
“sensitizers”, for example, Bad and Noxa, act only by dis-
placing the activators from the anti-apoptotic proteins,
allowing the activators to bind and activate Bax and Bak
[4,5]. The indirect model posits that BH3-only pro-
teins activate Bax and Bak not by binding either one,
but by antagonizing anti-apoptotic proteins that con-
strain Bax and Bak. In this scenario, Bim, Bid and
Puma proteins are far more potent than the others,
such as Bad and Noxa, because they can engage all
the anti-apoptotic proteins, while Bad and Noxa
selectively bind only a subset of anti-apoptotic pro-
teins [6,7].
Newmeyer et al. first revealed in a cell-free system that
the addition of Bcl-2 into the organelle fraction enriched
in mitochondria inhibited the process of nuclear de-
struction, the typical morphological change when cells
underwent apoptosis [8]. A good many studies have cu-
mulatively proven that anti-apoptotic Bcl-2 members are
attractive targets for anti-cancer therapy [9,10]. Numer-
ous anti-cancer strategies based on BH3 peptides derived
from BH3-only proteins [11], anti-sense oligonucleotide
or RNA interference targeting anti-apoptotic Bcl-2 fam-
ily proteins [12], and non-peptidic small molecules bind-
ing specifically to anti-apoptotic Bcl-2 proteins [10] have
been developed. Accordingly, substantial advances have
been achieved in the field of screening techniques, which
are critical to the identification and verification of antag-
onists against Bcl-2 anti-apoptotic proteins [13-15]. In
vitro high-throughput screening approaches utilizing
technologies like fluorescence polarization (FP) or nu-
clear magnetic resonance (NMR) were quite effective in
the discovery and selection of lead compounds suitable
for further optimization and development. However,
these methods lack the ability to mimic the intracellular
environment where the interruption of protein-protein
interaction actually happens. Cell-free systems using
mitochondria isolated from normal and cancer cells
[4,7,16,17] have been adopted to study mitochondrial
changes upon antagonizing Bcl-2 anti-apoptotic mem-
bers, which would serve as a promising tool closely
imitating the intracellular initiation of MOMP and apop-
totic core machinery to verify BH3 mimetics discovered
by other assays. Interestingly, similar system based on
isolated mitochondria was also used to characterize
compounds designed to target Bid to treat disorders
associated with the activation of such pro-apoptotic
protein [18].In this study, we set up a functional assay using mito-
chondria isolated from breast cancer cells, recombinant
anti-apoptotic Bcl-2 family proteins and different BH3
peptides. Experimental conditions under which BH3
peptides with selective targeting profiles induce MOMP
either alone or in combination were determined and op-
timized. In this assay, MOMP was allowed to be semi-
quantified by measuring the release of key apoptogenic
molecules (such as Cytochrome c and Smac) from mito-
chondrial intermembrane space using western blotting.
We optimized the experimental conditions by adopting
the high ionic strength (HIS) buffer during permeabiliza-
tion of mitochondria by BH3 peptides. We believe this
optimized functional assay based on MOMP will be a
useful screening and validation tool for identifying




2LMP, a subclone of MDA-MB-231, was kindly provided
by Dr. Marc Lippman (University of Miami). Normal
cell lines including WI-38, PrEC, and human breast
cancer cell lines including HBL100, SUM159, BT549,
MCF-7, T47D, ZR75.1, MDA-MB-134, MDA-MB-231,
MDA-MB-436, MDA-MB-453 and MDA-MB-468 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and cultured in medium
recommended by ATCC. 2LMP, MDA-MB-436 and
MDA-MB-453 were grown in RPMI 1640 containing
L-glutamine supplemented with 10% FBS and 1% Peni-
cillin/Streptomycin, maintained in antibiotic-free envir-
onment at 37°C in a 5% CO2 atmosphere and routinely
screened for Mycoplasma contamination. BH3 peptides
were kindly provided by Dr. Peter P Roller (Laboratory
of Medicinal Chemistry, National Cancer Institute), in-
cluding Bim BH3 peptide, both 21-mer and 26-mer
(residues 81–101: DMRPEIWIAQELRRIGDEFNA, resi-
dues 81–106: DMRPEIWIAQELRRIGDEFNAYYARR)
[Swiss-Prot: O43521], Bid BH3 peptide (residues 79–99:
QEDIIRNIARHLAQVGDSMDR) [Swiss-Prot: P55957],
Bad BH3 peptide (residues 103–128: NLWAAQRYGREL
RRMSDEFVDSFKKG) [GenBank:CAG46757], and Noxa
BH3 peptide (residues 18–43: PAELEVECATQLRRFG
DKLNFRQKLL) [Swiss-Prot: Q13794] [19]. ABT-737
was synthesized (>99% purity) according to the literature
[13]. All other chemicals used were purchased from
Sigma-Aldrich.
Protein expression and purification
Human Bcl-2 protein
The isoform 2 construct of the human Bcl-2 (NM_0006
33) was used to produce N-terminal 6×His tagged
recombinant protein in E. coli BL21 (DE3). Cells were
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0.6 at 37°C. Protein expression was then induced with
0.4 mM IPTG at 20°C for 20 h. After centrifugation, cell
pellets were resuspended in lysis buffer containing 50
mM Tris, pH 8.0, 500 mM NaCl, 0.1% BME and
Leupectin/Aprotin. After sonication and centrifugation,
recombinant protein was purified from the soluble frac-
tion first using Ni-NTA resin (QIAGEN), and then
Superdex75 column (Amersham Biosciences) in elution
buffer containing 25 mM Tris, pH 8.0, 150 mM NaCl
and 2 mM DTT.
Human Bcl-xL protein
Gene encoding human Bcl-xL protein (NM_138578),
which has an internal deletion of 45–85 amino acid
residues and a C-terminal truncation of 212–233, was
cloned into the pHis-TEV vector (a modified pET vec-
tor) to generate N-terminal 8xHis tagged recombinant
protein in E. coli BL21(DE3). The same protocols to ex-
press and purify human Bcl-2 protein were followed.
Lysis buffer contained 50 mM Tris, pH 7.5, 200 mM
NaCl, 0.1% BME and Leupectin/Aprotin, while protein
was eluted in buffer containing 20 mM Tris, pH7.5, 150
mM NaCl and 5 mM DTT.
Human Mcl-1 protein
The Mcl-1fragment (NM_021960) encoding amino acid
residues of 171–327 was cloned into the pHis-TEV vec-
tor. Mcl-1 protein with an N-terminal 8×His tag was
produced in E. coli BL21(DE3). The same protocols to
express and purify human Bcl-2 protein were followed
but a Source Q15 column was used in the second purifi-
cation step and protein was eluted in 25 mM Tris, pH
8.0, with NaCl gradient.
These recombinant proteins protect the mitochondria
from MOMP by sequestering the added Bim BH3 pep-
tide, until Bim BH3 is displaced by other BH3 molecules
targeting the recombinant proteins.
Fluorescence polarization (FP) based binding assays
Mcl-1 and Bcl-2 protein
A 21-residue Bid BH3 peptide (residues 79–99: QEDIIR
NIARHLAQVGDSMDR) [Swiss-Prot: P55957] was
synthesized and labeled at the N-terminus with 6-
carboxyfluorescein succinimidyl ester (FAM) as the
fluorescence tag (FAM-Bid). Saturation experiments
determined that FAM-Bid binds to Mcl-1 and Bcl-2 pro-
tein with a Kd values of 2.8 nM and 6.3 nM, respectively.
For competitive binding experiments, Mcl-1 protein (20
nM) or Bcl-2 protein (40 nM) were pre-incubated with
FAM-Bid peptide (2 nM and 2.5 nM respectively) in the
assay buffer (100 mM potassium phosphate, pH 7.5; 100
μg/ml bovine gamma globulin; 0.02% sodium azide, pur-
chased from Invitrogen, Life Technologies). 5 μl of asolution in DMSO of the tested BH3 peptide was added
to the protein/FAM-Bid solution in black, round-bottom
plates (Microfluor 2Black, Thermo Scientific) to produce
a final volume of 125 μl. For each experiment, a control
containing tested protein and Flu-Bid peptide (equiva-
lent to 0% inhibition), and another control containing
only FAM-Bid (equivalent to 100% inhibition), were in-
cluded on each assay plate. After 2–3 hours incubation,
the polarization values in milipolarization units (mP)
were measured at an excitation wavelength of 485 nm
and an emission wavelength of 530 nm using the Syn-
ergy H1 Hybrid Microplate Reader (BioTek). IC50, the
inhibitor concentration at which 50% of bound peptide
is displaced, was determined from the plot using
Nonlinear Least Squares analysis and curve fitting
performed using GraphPad Prizm 5 software (GraphPad
Software, San Diego, CA). The unlabeled Bid BH3 pep-
tide is used as the positive control. The Ki value for each
BH3 peptide was calculated using the equation we have
developed for FP-based assays [20].
Bcl-xL protein
For this assay, we have employed the Bak BH3 peptide
(residues 72–87: GQVGRQLAIIGDDINR) [Genebank:
AAA74466] labeled with fluorescein (FAM-Bak) instead
of the FAM-Bid to maximize the signal. It was deter-
mined that FAM-Bak has a Kd value of 5.6 nM to Bcl-xL
protein. The competitive binding assay for Bcl-xL was
the same as that for Mcl-1 and Bcl-2 with 30 nM of
Bcl-xL protein and 2.5 nM of FAM-Bak peptide in the
following assay buffer: 50 mM Tris-Bis, pH 7.4 and
0.01% bovine gamma globulin.
Surface plasmon resonance (SPR) based binding assay
Biotin-labeled Bim BH3 peptide (residues 81–106: DMR
PEIWIAQELRRIGDEFNAYY- ARR) [Swiss-Prot: O435
21] was immobilized on a streptavidin SA sensor chip,
while the Fc1 surface was used as a control surface. The
binding affinities of recombinant Mcl-1, Bcl-2 and
Bcl-xL to immobilized Bim BH3 peptide was determined
by injecting proteins in different concentrations in HBS-
EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM
EDTA, 0.005% v/v P20). Determination of kon, koff and
Kd were calculated by simultaneous non-linear regres-
sion using BIAevaluation software (BIAcore Life Sci-
ences). Bim peptide has a Kd values of 0.2 nM, 1.4 nM
and 0.3 nM against Mcl-1, Bcl-2 and Bcl-xL, respect-
ively. The obtained results confirmed the high binding
affinity of Bim BH3 peptide against all three members
from the Bcl-2 family of proteins.
Using the same Bim BH3 peptide immobilized SA
chip, SPR competitive solution binding experiments
were performed by pre-incubating tested proteins (20
nM) with tested BH3 peptides for at least 30 minutes
Figure 1 Breast cancer cells are dually or multiply-protected by anti-apoptotic Bcl-2 family proteins. Cell lines were cultured under
conditions recommended by ATCC. Whole cell lysates were subjected to SDS-PAGE and Western blotting analysis for the basal level of three
major anti-apoptotic Bcl-2 family proteins, Bcl-2, Bcl-xL and Mcl-1.
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faces of the chip. Response units were measured at 30
seconds in the dissociation phase and the specific bind-
ing was calculated by subtracting the control surface
(Fc1) signal from the surfaces with immobilized Bim
BH3 peptide. IC50 values were determined by Non-linear
Least Squares analysis using Graph Pad Prism 5.0
software.
Isolation of breast cancer cell mitochondria
Mitochondria were isolated from breast cancer cells.
Cells were harvested by centrifugation at 1200 g (Micro
centrifuge 5415R from Eppendorf ) for 5 min at 4°C and
then washed with ice-cold PBS. Cell pellets were
resuspended in 400 μl of mitochondria isolation buffer
(MIB: pH 7.4; 0.1 mM EDTA, 10 mM Tris–HCl, 250
mM Sucrose) freshly added 1 mM PMSF and Protease
Inhibitor Cocktail (Roche). Cell suspensions were then
homogenized with 40 strokes in a Dounce Tissue
Grinder on ice and centrifuged at 1200 g for 10 min at
4°C. Supernatants were centrifuged at 12000 g for 10
min at 4°C. Pellet enriched in mitochondria was washed





IC50[nM] ± SD IC50[nM] ± SD IC50[nM]
Bid 51.21 ± 0.42 5.86 ± 1.81 60.11 ±
Bad 4.37 ± 0.4 8.64 ± 7.49 >300
Bim 1.26 ± 0.09 1.42 ± 0.07 1.33 ±
Noxa >30000 >30000 51.0 ±
BH3 peptides were screened for their binding affinities to the three anti-apoptotic B
polarization methods, as described in the Methods. Results are representative of atat 4°C. The pellet was then resuspended in appropriate
volume of mitochondria reaction buffer (MRB), freshly
added 1 mM PMSF and Protease Inhibitor Cocktail. In
order to optimize buffer condition during permeabiliza-
tion of mitochondrial outer membrane, two different
(MRB) solutions were used. Low ionic strength (LIS)
buffer contained 20 mM HEPES (pH 7.4), 10 mM KCl,
1.5 mM MgCl2, 1 mM EDTA, and 250 mM sucrose [21].
High ionic strength (HIS) buffer contained 20 mM
HEPES (pH 7.5), 100 mM KCl, 2.5 mM MgCl2, and 250
mM sucrose [22]. Protein concentrations were deter-
mined using Bradford Protein Assay (Protein Assay Kit
II, Cat# 500–0002, Bio-Rad). The mitochondrial suspen-
sions were aliquoted into 50 μl with 1 mg/ml protein
concentration for permeabilization experiments.
Permeabilization of mitochondrial outer membrane by
BH3 peptides or ABT-737
For experiments using peptide or ABT-737 alone, mito-
chondria were incubated with solvent (less than 0.5%
DMSO), different concentrations of Bim, Bad, Noxa
BH3 peptides, or ABT-737 for 1 h in 37°C water bath.
For experiments using recombinant proteins andee major anti-apoptotic Bcl-2 family proteins
FP assay
1 Bcl-2 Bcl-xL Mcl-1
± SD Ki[nM] ± SD Ki[nM] ± SD Ki[nM] ± SD
16.8 11.2 ± 1.4 8.8 ± 1.5 6.0 ± 3.3
00 7.1 ± 0.7 3.2 ± 0.4 >20000
0.06 ≤1 ≤1 ≤1
13.6 >10000 >10000 97 ± 7.7
cl-2 family proteins using surface plasmon resonance and fluorescence
least three independent experiments.
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pretreated with PBS or recombinant proteins (Bcl2, Bcl-
xL and Mcl-1) followed by permeabilization with solvent
(less than 0.5% DMSO) or different concentrations of
BH3 peptides. At the end of incubation, mitochondria
were pelleted at 12000 g for 15 min at 4°C, supernatants
were collected and briefly heated with 2 × sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer. Mitochondrial pellets were also
dissolved and heated in 2 × SDS-PAGE sample buffer.
Both the supernatant samples and mitochondrial pellet
samples were subjected to immunoblotting against Cyto-
chrome C and Smac/Diablo proteins.
Western blot analysis of released cytochrome C and smac
protein
Supernatant samples and mitochondrial pellet samples
were subjected to protein separation by SDS-PAGE.
After transfer to Polyvinylidene fluoride (PVDF) mem-
branes, Cytochrome C, Smac proteins and loading con-
trol (Cytochrome C Oxidase IV, COX IV) were analyzed
using the following primary antibodies: anti-Cytochrome
C polyclonal antibody (1:500; #4272; Cell Signaling
Techonology), anti-Smac/DIABLO polyclonal antibody
(1:500; PC574; Calbiochem), anti-COX IV monoclonal
antibody (3E11; 1:1000; #4850; Cell Signaling Techono-
logy). Blots were then probed with species-specific
horseradish peroxidase-conjugated secondary antibodies
(Thermo Scientific) and detected with chemilumines-
cence (Thermo Scientific). For supernatant samples, one
blot was cut into two parts so that both Cytochrome CFigure 2 Sufficient ionic strength from KCl ensured reliable Cytochro
peptides. 2LMP mitochondria were isolated in mitochondrial isolation buf
Sucrose and permeabilized by Bim BH3 peptides (26-mer unless otherwise
containing 20 mM HEPES 1.5 mM MgCl2, 1 mM EDTA, 250 mM sucrose, an
release of Cytochrome C and Smac proteins was confirmed by densitomet
indicated concentrations for 30 min or 60 min in either high ionic strength
10 mM KCl (B). Mitochondrial pellets (P) and supernatants (S) were carefully
were subjected to SDS-PAGE and Western blotting analysis for Cytochrome
experiments. *: 21-mer Bim BH3 peptide.and Smac could be detected simultaneously without
reprobing. For pellet samples, the blot was probed for
Cytochrome C, Smac, as well as COX IV that served as
loading control.
Results and discussion
Breast cancer cells are dually or multiply-protected by
anti-apoptotic Bcl-2 family proteins
As we know, cancer cells are dually-, triply-, or multiply-
protected by Bcl-2, Bcl-xL, Mcl-1 or other anti-
apoptotic Bcl-2 family proteins which have been less
thoroughly studied. A panel of human normal cell lines
and breast cancer cell lines were analyzed by Western
blotting for their basal levels of three key anti-apoptotic
proteins, Bcl-2, Bcl-xL and Mcl-1 (Figure 1). 2LMP cell
line, a subclone of MDA-MB-231, is characterized by its
abundant cytoplasm and rapid proliferation which are
critical for providing sufficient mitochondria. Both
MDA-MB-436 and MDA-MB-453 expressing mainly
Mcl-1 protein were suitable cell line models for studying
MOMP induced by Noxa-like molecules and the com-
bined outcome from co-treatment with both Bad-like
and Noxa-like molecules.
BH3 peptides derived from BH3-only proteins were
powerful tools for setting up conditions of the
mitochondria-based functional assay
Binding affinities of BH3 peptides to Bcl-2, Bcl-xL and
Mcl-1 recombinant proteins were determined by surface
plasmon resonance (SPR) and fluorescence polarization
(FP), as shown in Table 1. Bim (26-mer) and Bid BH3me C and Smac release from mitochondria permeabilized by BH3
fer (MIB pH 7.4) containing 10 mM Tris–HCl, 0.1 mM EDTA, 250 mM
indicated) for 60 min in mitochondrial reaction buffer (MRB pH 7.4)
d different concentrations of KCl (A). The ionic strength-dependent
ry analysis (A). 2LMP mitochondria were permeabilized by Bim BH3 at
buffer containing 100 mM KCl or low ionic strength buffer containing
separated and mixed with sample buffer, and equivalent portions
C and Smac/Diablo. Results are representative of three independent
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ities. Bad BH3 peptide bound to both Bcl-2 and Bcl-xL,
but failed to find to Mcl-1, as expected. Noxa BH3 pep-
tide selectively bound to Mcl-1 protein only. Although
there was some discrepancy between the SPR and the FP
data, probably due to different assay conditions, data re-
garding the versatility of Bim BH3 and the selectivity of
Bad and Noxa BH3 were highly consistent with the
literature [4,23]. Mitochondria based-functional assay
established by using these peptides will help to define how
and when Bim-like, Bad-like or Noxa-like small molecule
Bcl-2 inhibitors function on the mitochondrial level.
Sufficient ionic strength from KCl ensured reliable
cytochrome C and smac release from mitochondria
permeabilized by BH3 peptides
Previous apoptosis studies using purified mitochondria
as a cell-free system have yielded conflicting results due
to less appropriate experimental conditions including
low ionic strength [22], physiologically irrelevant tempe-
rature [7] or short incubation time [24]. These studiesFigure 3 Comparison of MOMP induction by different BH3 peptides a
different anti-apoptotic Bcl-2 family proteins. 2LMP mitochondria were
indicated concentrations (A). 2LMP mitochondria were pre-treated with bu
concentration before being permeablized by Bim BH3 peptide (B). Mitocho
mixed with sample buffer, and equivalent portions were subjected to SDS-
Diablo. Results are representative of three independent experiments.provided substantial evidence that sufficient ionic
strength and temperature of 37°C contributed to full re-
lease of Cytochrome C. In our study, ionic strength-
dependent release of Cytochrome C was also confirmed
in mitochondria permeabilized by Bim BH3 peptide in
60 min in buffer containing different concentrations of
KCl (Figure 2A). Mitochondria isolated from 2LMP cells
were incubated with Bim BH3 (21-mer and 26-mer)
peptides at 37°C for 30 min or 60 min in either high
ionic strength (HIS)buffer containing 100 mM KCL or
low ionic strength (LIS) buffer containing 10 mM KCl.
MOMP induced by Bim BH3 peptides at indicated con-
centrations were evaluated through the analysis of re-
leased Cytochrome C and Smac proteins by Western
blotting. As shown in Figure 2B, Bim BH3 peptide in-
duced MOMP in a dose-dependent manner. Bim BH3
peptide induced significantly more robust release of
Cytochrome C and Smac proteins when there was suffi-
cient ionic strength from KCl. Preliminary FP data sug-
gested that the binding affinity of 21-mer Bim BH3
peptide was weaker than 26-mer Bim BH3 peptide (datand the abilities to repress Bim BH3 peptide-induced MOMP by
isolated and permeabilized by different BH3 peptide and ABT-737 at
ffer alone or recombinant Bcl-2, Bcl-xL, or Mcl-1 proteins at indicated
ndrial pellets (P) and supernatants (S) were carefully separated and
PAGE and Western blotting analysis for Cytochrome C and Smac/
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Smac release by 21-mer Bim (Figure 2B, lane 10) was
weaker than that by 26-mer Bim (Figure 2B, lane 8).
Longer incubation resulted in more complete release of
Cytochrome C, as indicated by more Cytochrome C be-
ing detected in the supernatant fraction and less Cyto-
chrome C remained in the pellet fraction of treatment
with 25 nM Bim for 60 min in HIS buffer (Figure 2B,
Lane 5), compared with similar treatment for 30 min
(Figure 2B, Lane 2). Hence, 26-mer Bim BH3 peptide,
reaction buffer containing 100 mM KCl, reaction
temperature of 37°C and incubation time of 60 min were
set as experimental conditions for all mitochondrial
experiments.
Comparing the efficiency of MOMP induction by dif-
ferent Bcl-2 targeting agents and functional inhibition of
Bim BH3 peptide-induced MOMP by three different
anti-apoptotic Bcl-2 family proteins.
Mitochondria isolated from 2LMP cells were perme-
abilized by Bim, Bid, Bad, Noxa BH3 peptides and ABT-
737, a bona fide Bcl-2 antagonist, as shown in Figure 3A.Figure 4 Titrating Mcl-1 exogenous protein to find out the condition
selectivity. 2LMP mitochondria were pre-treated with buffer alone or reco
escalated concentration (B, C) before being permeablized by Bim BH3 pep
concentrations. 2LMP mitochondria pre-treated with buffer alone or 200 nM
concentrations of Bim BH3 peptide which antagonized all three anti-apopt
25 nM of Bim BH3 peptide (D). Mitochondrial pellets (P) and supernatants
equivalent portions were subjected to SDS-PAGE and Western blotting ana
three independent experiments. N*: Noxa BH3 peptide.Bim, Bid, Bad BH3 peptides and ABT-737 effectively in-
duced Cytochrome C and Smac release from 2LMP mito-
chondria. Consistent with its binding affinities to Bcl-2,
Bcl-xL and Mcl-1 proteins, Bim BH3 peptide was the
most potent inducer among all BH3 peptides. Noxa alone
was not able to induce Cytochrome C and Smac release,
which is also consistent with previous reports [25]. Bim
BH3 induced robust release of Cytochrome C and Smac
proteins even at 25 nM. The three major anti-apoptotic
proteins were equally potent in repressing the induction of
MOMP by 25 nM Bim BH3 peptide. Even 10 nM of re-
combinant protein is enough to fully abolish Bim BH3-
induced Cytochrome C and Smac release (Figure 3B).
Titrating Mcl-1 exogenous protein to find out the
condition in which both Bad and Noxa BH3 peptides
exhibit their binding selectivity
2LMP mitochondria were mixed with 25 nM of either
Bcl-2 or Mcl-1 proteins. Under the inhibition of Mcl-1,
25 nM of Bim was unable to induce Smac or Cyto-
chrome c release. Though not able to induce MOMP inin which both Bad and Noxa BH3 peptides exhibit their binding
mbinant anti-apoptotic Bcl-2 proteins at low concentration (A), at
tide together with Bad or Noxa BH3 peptides at indicated
of Bcl-2, Bcl-xL or Mcl-1 were incubated with different
otic proteins to recover Cytochrome C and Smac release induced by
(S) were carefully separated and mixed with sample buffer, and
lysis for Cytochrome C and Smac/Diablo. Results are representative of
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tide was able to overcome the protection conferred by
Mcl-1, but not Bcl-2. On the other hand, Bad BH3 pep-
tide can overcome the protection conferred by both Bcl-
2 and Mcl-1 proteins, as shown in Figure 4A. This was
probably because the combination of Bim and Bad BH3
peptides generated enough de-repressing effect on mito-
chondria moderately protected by either Bcl-2 or Mcl-1
proteins due to the promiscuous nature of Bim, while
the combination of Bim and Noxa BH3 peptides could
not provide such synergism when Bim BH3 peptide was
fully neutralized by Bcl-2 protein. Since both Bad and
Noxa BH3 peptides were able to restore Bim BH3
peptide-induced MOMP in 2LMP mitochondria moder-
ately protected by Mcl-1, the functional assay established
under such concentration of recombinant protein would
fail to demonstrate the selectivity and specificity of ei-
ther Bcl-2 or Mcl-1 antagonists. Hence, appropriate con-
centrations of protein had to be determined to ensure
discrimination between Bad-like and Noxa-like mito-
chondrial permeabilizers. As shown in Figure 4B, the
synergistic effect of Bad BH3 peptide on Bim-inducedFigure 5 The combination of Bad and Noxa BH3 peptides provided sy
protected by Mcl-1 protein. 2LMP mitochondria were pre-treated with b
permeablized by Bim BH3 peptide alone, Bim BH3 peptide together with B
BH3 peptides simultaneously without the presence of Bim BH3 peptide (A)
permeabilized by different concentrations of Bim, Bad or Noxa BH3 peptide
concentrations (B). Mitochondrial isolated from MDA-MB-453 cell line were
peptides alone or Bad and Noxa BH3 peptides simultaneously at indicated
mitochondria isolated from MDA-MB-436, 2LMP and MDA-MB-453 cells wa
carefully separated and mixed with sample buffer, and equivalent portions
indicated proteins. Results are representative of three independent experimMOMP was diminished when escalated concentrations
of Mcl-1 protein were applied, and completely abolished
under 200 nM of Mcl-1 protein, while the effect of Noxa
BH3 peptide was intact. On the other hand, Bad BH3
peptide could still successfully synergize with Bim BH3
peptide in the induction of MOMP in 2LMP mitochon-
dria protected by the same amount of either Bcl-2 or
Bcl-xL proteins (Figure 4C), indicating that a concentra-
tion of recombinant protein up to 200 nM was necessary
to ensure reliable assay results of selectivity and specifi-
city of BH3 peptides. As it is a promiscuous BH3 peptide
targeting all three anti-apoptotic proteins, the Bim BH3
peptide overcame the protection of all three proteins
with similar efficacy (Figure 4D).
The combination of Bad and Noxa BH3 peptides provided
synergism in the induction of MOMP in mitochondria
dominantly protected by Mcl-1 protein
2LMP mitochondria were pre-incubated with 200 nM
Mcl-1 recombinant protein. Noxa and Bad BH3 peptides
were added alone or in combination in the presence or
absence of 25 nM of Bim BH3 peptide as indicated. Asnergism in the induction of MOMP in mitochondria dominantly
uffer alone or recombinant Mcl-1 protein at 200 nM before being
ad or Noxa BH3 peptides at indicated concentrations, Bad and Noxa
. Mitochondrial isolated from MDA-MB-436 cell line were
s alone or Bad and Noxa BH3 peptides simultaneously at indicated
permeabilized by different concentrations of Bim, Bad or Noxa BH3
concentrations (C). The presence of Bcl-2, Bcl-xL or Mcl-1 proteins on
s shown (D). Mitochondrial pellets (P) and supernatants (S) were
were subjected to SDS-PAGE and Western blot analysis for the
ents. N*: Noxa BH3 peptide.
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can permeabilize the mitochondria even at 10 μM. Bad
BH3 peptide, when used up to 10 μM, hardly recovered
any release of Bim BH3 peptide-induced Cytochrome C
release, while Noxa BH3 peptide fully restored the effect
of Bim BH3 peptide repressed by overly abundant Mcl-1
protein. In the absence of Bim BH3 peptides, Bad and
Noxa BH3 peptides synergized with each other in per-
meabilizing the mitochondria dominantly protected by
Mcl-1 protein. Neither Bad (at 10 μM) nor Noxa BH3
peptide (at 3 μM) could overcome the repression on
Bim BH3 peptide-mediated MOMP by 200 nM Mcl-1
protein. However, the combination of Bad and Noxa
BH3 peptides, both at 1 μM, significantly induced
MOMP in mitochondria protected dominantly by Mcl-1.
Therefore, mitochondria isolated from cell lines
protected mainly by Mcl-1 were perfect models to dem-
onstrate synergism between Bad and Noxa BH3 pep-
tides. Both MDA-MB-436 and MDA-MB-453 cells
expressed abundant Mcl-1. We hypothesized that mito-
chondria from these two cell lines protected dominantly
by Mcl-1 would behave in the same pattern as 2LMP
mitochondria protected by overly abundant recombinant
Mcl-1 protein. MDA-MB-436 cells expressed high level
of Mcl-1, moderate level of Bcl-xL and undetectable
Bcl-2. As shown in Figure 5B, both Bim and Bad BH3
peptides effectively induced MOMP, while Noxa alone,
up to 10 μM, failed to induce MOMP in mitochondria
isolated from this cell line, as expected. However, in the
absence of Bim, combination of Bad and Noxa BH3 pep-
tides induced MOMP comparable to that induced by
Bim BH3 peptide. MDA-MB-453 cells expressed trace
amount of Bcl-xl and undetectable Bcl-2, hence the
mitochondria were protected mainly by Mcl-1 protein.
As shown in Figure 5C, Bim BH3 peptide effectively in-
duced MOMP, while Noxa BH3 peptide alone did not
induce any release of mitochondrial intermembrane
space proteins. Bad BH3 peptide alone, up to 10 μM, in-
duced the release of moderate amount of Smac and
barely detectable Cytochrome C from MDA-MB-453
mitochondria. In the absence of Bim, Bad BH3 peptide
and Noxa BH3 peptide induced synergistic release of
Cytochrome C and Smac protein from MDA-MB-453
mitochondria, further confirming the necessity of the
involvement of Noxa-like molecule in permeabilizing
mitochondria dominantly protected by Mcl-1 protein
(Figure 5D).
In this study, we have optimized the condition of a
mitochondria-based cell-free system to verify the BH3
peptides with selective targeting profile, facilitating fu-
ture identification of inhibitors against Bcl-2, Bcl-xL, or
Mcl-1. We obtained reliable results on Cytochrome C
and Smac release by adopting several conditions sug-
gested by other groups and also confirmed by us. Mostimportantly, we have set up protocols using either 2LMP
mitochondria protected by recombinant Bcl-2 anti-
apoptotic proteins or mitochondria purified from two
other breast cancer cell lines dominantly protected by
endogenous Mcl-1 to demonstrate a clear synergistic ef-
fect on the induction of MOMP by the combination of
Bad and Noxa BH3 peptides.
There are several reasons why we chose to use mito-
chondria isolated from cancer cells as our experimental
subjects and semi-quantify Cytochrome C and Smac re-
lease by western blotting. First of all, the Bcl-2 family
proteins regulates the integrity of the outer mitochon-
drial membrane that can be permeabilized when the
balance between pro-apoptotic and anti-apoptotic Bcl-2
proteins is interrupted by effective BH3 mimetics,
resulting in MOMP followed by the release of the mito-
chondrial intermembrane space proteins detectable in
many testing methods [25-27]. Secondly, cell-free system
simplifies protein studies by eliminating the possibility
of transcriptional or posttranslational modifications.
Thirdly, use of western blotting to detect MOMP does
not need dedicated laboratory equipments and can easily
be carried out in almost all laboratories. However, the
disadvantages of this functional assay method include
low throughput, lack of sensitivity and need for artifact-
prone subcellular fractionation [27]. The use of this
technique may be limited to verification of BH3 mi-
metics with decent binding affinities to Bcl-2 family pro-
teins, hence it should be recommended to serve as a
complement to screening methods with higher sensitiv-
ity, like FP or ELISA.
Conclusions
The mitochondrial functional assay based on MOMP is a
robust screening and validation tool for identifying BH3
mimetics with selective toxicity profile and investigating
their mechanism of action on breast cancer cell lines
protected by different anti-apoptotic Bcl-2 family proteins.
It represents a reliable and predictive screening tool that is
complementary to high throughput screening to further
verify promising lead compounds on a functional level.
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